September 2025 – December 2025

Jonathan Alder, PhD // Pulmonary, Allergy, Critical Care, and Sleep Medicine
UPMCE TS: A Safe Mechanism to Lengthen Telomeres and Promote Tolerance of Immune Suppression
UPMC Enterprises SRA00005690
Start Date: November 24, 2025
End Date: November 23, 2026
Total Costs: $410,097

Jaideep Behari, MD, PhD // Gastroenterology, Hepatology and Nutrition
MASLD Early Detection, Treatment Optimization and Referral Network (METEOR Net)
Madrigal Pharmaceuticals, Inc.SRA00006389
Start Date: November 3,2025
End Date: October 31, 2027
Total Costs: $431,250

Juliane Beier, PhD // Gastroenterology, Hepatology and Nutrition
The East Palestine Train Derailment Health Research Program
OT2 ES038710
Start Date: September 25, 2025
End Date: August 31, 2026
Total Costs: $440,513

David Binion, MD // Gastroenterology, Hepatology and Nutrition
Precision guided therapeutics for inflammation and fibrosis therapy in IBD. Phase II: tissue explant studies
Mirador Therapeutics SRA00005709
Start Date: October 23, 2025
End Date: October 22, 2028
Total Costs: $980,898

Randall Brand, MD // Gastroenterology, Hepatology and Nutrition
ClearNote Health Pancreatic Cancer Biomarker Collaboration
ClearNote Health SRA00006232
Start Date: November 26, 2025
End Date: November 25, 2028
Total Costs: $193,700

Randall Brand, MD // Gastroenterology, Hepatology and Nutrition
Retrospective Cases to Assist in Determining Specimen Requirements for Assay Development
Singlera Genomics, Inc. SRA00006173
Start Date: October 27, 2025
End Date: October 26, 2027
Total Costs: $38,200

Andreea Coca, MD, MPH // Rheumatology and Clinical Immunology
SLE Treatment with N-acetylcysteine
Research Foundation for the State University of New York 1162484-100823
Start Date: November 1, 2024
End Date: May 31, 2025
Total Costs: $63,105

Robyn Domsic, MD, MPH // Rheumatology and Clinical Immunology
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational
Scleroderma Research Foundation SRF201
Start Date: December 1, 2025
End Date: August 31, 2028

Paul Joudrey, MD, MPH, and Cristina Murray-Krezan, PhD // General Internal Medicine
PeRsOnlized MethadOne TrEatment (PROMOTE) by implementing shared decision making
R61 DA063659
Start Date: September 30, 2025
End Date: August 31, 2027
Total Costs: $488,334

Georgios Kitsios, MD, PhD // Pulmonary, Allergy, Critical Care, and Sleep Medicine
Exhaled Breath as a Noninvasive Approach for LRTI Diagnosis
Zeteo Tech, Inc.
Start Date: July 1, 2025
End Date: June 30, 2026
Total Costs: $246,080

Nicoletta Machin, DO, MS // Classical Hematology
Vega Therapeutics VGA039-CP002SRA00006225
Start Date: October 7, 2025
End Date: October 6, 2030
Total Costs: $112,641

Siamak Moghadam-Kia, MD, MPH // Rheumatology and Clinical Immunology
Clinical Response to Standard of Care Treatment in Moderate to Severe Refractory Myositis in Natural History Database
Cabaletta Bio, Inc. SRA00006318
Start Date: November 3, 2025
End Date: November 2, 2027
Total Costs: $401,170

Urvi Parikh, PhD // Infectious Diseases
Population Council
Start Date: November 1, 2025
End Date: October 31, 2028
Total Costs: $139,292

Urvi Parikh, PhD // Infectious Diseases
Leidos 23X021 TO 11
Start Date: November 18, 2025
End Date: August 30, 2026
Total Costs: $75,000

Shari Rogal, MD, MPH // Gastroenterology, Hepatology and Nutrition
Implementing lifestyle change interventions to improve health outcomes
CDC U48 DP006942
Start Date: September 29, 2025
End Date: September 28, 2027
Total Annual Costs: $492,348

Daniella Schwartz, MD // Rheumatology and Clinical Immunology
Identifying CXCL9-high patients with rheumatic diseases
Sobi Pharmaceuticals SRA00006175
Start Date: November 20, 2025
End Date: November 19, 2027
Total Costs: $30,000

Ryan Shields, PharmD, MS // Infectious Diseases
AbbVie Inc. SRA00006086
Start Date: October 24, 2025
End Date: N/A
Total Costs: $694,698

Ryan Shields, PharmD, MS // Infectious Diseases
Merck Sharp & Dohme Corp. SRA00006043
Start Date: November 11, 2025
End Date: N/A
Total Costs: $243,755

Melanie Weltman, PharmD // Renal-Electrolyte
Barriers and Facilitators to Evidence Based Management of Cardiovascular Kidney Metabolic Syndrome
Dialysis Clinic, Inc. C-4232
Start Date: October 1, 2025
End Date: June 30, 2026
Total Costs: $100,000